Your provider should assess pancreatitis risk and concurrent medications before initiation
After observation, detailed aftercare instructions are provided to achieve ideal outcomes
Historically, the obesity pharmacotherapy literature notes early trial signals and also that development was terminated after failure to show meaningful weight loss in a larger, longer trial (as summarized in a peer-reviewed review discussing a 12-week signal and a later 24-week negative result)
While other brain cell types, such as astrocytes and microglia, may be responsive to slightly higher doses, they too benefit from lower sulforaphane doses (Subedi et al., 2019
Insulin resistance drives androgen production
Heres the short answer: Yes, theres an opportunity